Androgen Dependence of Hirsutism, Acne, and Alopecia in Women: Retrospective Analysis of 228 Patients Investigated for Hyperandrogenism
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Hirsutism, acne, alopecia, and oligo-amenorrhea are clinical expressions of hyperandrogenism, one of the most frequent endocrine disorders in women of reproductive age. Women referred to our endocrine clinics for skin symptoms of hyperandrogenism underwent a laboratory workup to evaluate hormone measurements and received antiandrogen therapy. We retrospectively analyzed the outcome of 228 consecutive patients investigated over 6 years.Patients with hirsutism had higher levels of androstenedione, dehydroepiandrosterone sulfate (DHEAS), and salivary testosterone; lower levels of sex hormone-binding globulin (SHBG); and a higher prevalence of oligo-amenorrhea than patients with alopecia, while patients with acne showed intermediate values. Hirsutism score correlated positively with androstenedione, DHEAS, and salivary testosterone, and correlated negatively with SHBG; salivary testosterone showed the highest correlation coefficient. Total testosterone was not significantly different among patients with hirsutism, alopecia, or acne, and did not significantly correlate with hirsutism score. Hirsutism and oligo-amenorrhea were the most sensitive symptoms of hyperandrogenism, and no androgenic parameter alone allowed us to identify all cases of hyperandrogenism.Patients of central European origin sought consultation with milder hirsutism scores than patients of southern European origin. There was, however, no difference in the clinical-biological correlation between these groups, arguing against differences in skin sensitivity to androgens.Polycystic ovary syndrome, defined as hyperandrogenism (hirsutism or elevated androgens) and oligo-amenorrhea, was diagnosed in 63 patients (27.6%), an underestimate compared with other reports that include systematic ovarian ultrasound studies. Neither pelvic ultrasound, used in a limited number of cases, nor the luteinizing hormone/follicle-stimulating hormone ratio helped to distinguish patients with polycystic ovary syndrome from the other diagnostic groups. These included hyperandrogenism (hirsutism or elevated androgens) and eumenorrhea (101 patients; 44.3%); normal androgens (acne or alopecia and eumenorrhea) (51 patients; 22.4%); isolated low SHBG (7 patients; 3.1%); nonclassical congenital adrenal hyperplasia (4 patients; 1.8% of total, 4.9% of patients undergoing cosyntropin stimulation tests); and ovarian tumor (2 patients; 0.9%).Ethinylestradiol and high-dose cyproterone acetate treatment lowered the hirsutism score to 53.5% of baseline at 1 year, and was also effective in treating acne and alopecia. The clinical benefit is ascribed to the peripheral antiandrogenic effect of cyproterone acetate as well as the hormone-suppressive effect of this combination. Salivary testosterone showed the most marked proportional decrease of all the androgens under treatment. Cost-effectiveness and tolerance of ethinylestradiol and high-dose cyproterone acetate compared well with other antiandrogenic drug therapies for hirsutism. The less potent therapy with spironolactone only, a peripheral antiandrogen without hormone-suppressive effect, was effective in treating isolated alopecia in patients with normal androgens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“Under these conditions, free testosterone may well be elevated and may show good clinical correlation,(11) but measuring it has limitations in terms of sensitivity, accuracy, and practicability.(48,51) For that reason salivary testosterone has been proposed as a surrogate measurement for circulating free testosterone,…”
BackgroundAndrogen Excess in Women: Experience with Over 1000 Consecutive Patients
Azziz, R., Sanchez, L. A., Knochenhauer, E. S., Moran, C., Lazenby, J., Stephens, K. C., Taylor, K., & Boots, L. R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031122 · Cited by 1,132 · cited 4×
“Hyperandrogenism is one of the most frequent endocrine disorders, considered to affect 5%Y10% of reproductive-aged women in different regions of the world.(6) Androgens are necessary for the physiologic development of the pilosebaceous unit.”
BackgroundInfluentialAndrology: Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients
Balen, A. H., Conway, G. S., Kaltsas, G., Techatraisak, K., Manning, P. J., West, C., & Jacobs, H. S. (1995) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a136243 · Cited by 1,060
Role of Hormones in Pilosebaceous Unit Development
Deplewski, D., & Rosenfield, R. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.4.0404 · Cited by 443 · cited 1×
“Under the action of androgens, villous hair becomes terminal hair in skin areas where women have considerably less hair than men.(14,38) Studies have demonstrated increased androgen production by the ovaries and the adrenals of women with hirsutism.”
BackgroundGambineri, A., Pelusi, C., Genghini, S., Morselli‐Labate, A. M., Cacciari, M., Pagotto, U., & Pasquali, R. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.01973.x · Cited by 216 · cited 1×
“Consequently, the effect of metformin on hirsutism was also modest and inconsistent.(1,20,25,34) The available antiandrogenic therapies for hirsutism are listed by efficacy in Figure 1, with mention of their respective costs.”
BackgroundOligoanovulation with Polycystic Ovaries But Not Overt Hyperandrogenism
Dewailly, D., Catteau-Jonard, S., Reyss, A.-C., Leroy, M., & Pigny, P. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1054 · Cited by 198 · cited 1×
“Although leaving polycystic ovary syndrome undiagnosed implies neglecting an increased risk of metabolic syndrome in these patients, it must be pointed out that the inclusion of the ultrasound criteria in the definition of polycystic ovary syndrome remains controversial, that the presence of polycystic ovarian morphol…”
BackgroundCosma, M., Swiglo, B. A., Flynn, D. N., Kurtz, D. M., LaBella, M. L., Mullan, R. J., Elamin, M. B., Erwin, P. J., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2429 · Cited by 129 · cited 1×
“These may be sufficient to contribute to the observed improvement in ovulation and fertility,(42) but not to induce any relevant effect on hirsutism, where antiandrogens are clearly more efficient.(12,58) Consequently, the effect of metformin on hirsutism was also modest and inconsistent.”
BackgroundLabrie, F., Luu-The, V., Labrie, C., Pelletier, G., & El-Alfy, M. (2000) · Hormone Research in Paediatrics · doi:10.1159/000053264 · Cited by 128 · cited 1×
“Another reason for poor correlation is that conversion rates of androgen precursors dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), and androstenedione, into testosterone and dihydrotestosterone, are not evaluated on clinical grounds although they may present important individual variations.(29)…”
Background
Cited by
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Martin, K. A., Chang, R. J., Ehrmann, D. A., Ibanez, L., Lobo, R. A., Rosenfield, R. L., Shapiro, J., Montori, V. M., & Swiglo, B. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2437 · Cited by 512
Martin, K. A., Anderson, R. R., Chang, R. J., Ehrmann, D. A., Lobo, R. A., Murad, M. H., Pugeat, M. M., & Rosenfield, R. L. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00241 · Cited by 339
Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review
Layton, A. M., Eady, E. A., Whitehouse, H., Del Rosso, J. Q., Fedorowicz, Z., & van Zuuren, E. J. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0245-x · Cited by 126
Amiri, M., Ramezani Tehrani, F., Nahidi, F., Bidhendi Yarandi, R., Behboudi‐Gandevani, S., & Azizi, F. (2017) · Clinical Endocrinology · doi:10.1111/cen.13389 · Cited by 57
Metadata
- Authors
- Karrer-Voegeli, S., Rey, F., Reymond, M. J., Meuwly, J.-Y., Gaillard, R. C., & Gomez, F.
- Venue
- Medicine
- Published
- 2009-01
- Volume
- 88
- Issue
- 1
- Pages
- 32-45
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2057272324
- Cited by
- 124
- References
- 11
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Androgen Dependence of Hirsutism, Acne, and Alopecia in Women: Retrospective Analysis of 228 Patients Investigated for Hyperandrogenism. https://app.cochat.ai/papers/10.1097/md.0b013e3181946a2c
- The paper
- Karrer-Voegeli, S., Rey, F., Reymond, M. J., Meuwly, J.-Y., Gaillard, R. C., & Gomez, F. (2009). Androgen Dependence of Hirsutism, Acne, and Alopecia in Women: Retrospective Analysis of 228 Patients Investigated for Hyperandrogenism. Medicine. https://doi.org/10.1097/md.0b013e3181946a2c
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.